SCHEMBL6602290

SCHEMBL6602290

O=c1[nH]c(Cc2cccc(O)c2)cc2ccccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 1/20 0.54
PARP1 P09874 3/20 0.52
CDK4 P11802 1/20 0.48
CCND1 P24385 1/20 0.48
CDK2 P24941 1/20 0.48
OPRK1 P41145 1/20 0.47
CDC25B P30305 3/20 0.47
KDM4E B2RXH2 2/20 0.45
GAA P10253 1/20 0.45
DAO P14920 1/20 0.41
ALDH1A1 P00352 2/20 0.40
APAF1 O14727 2/20 0.40
CASP3 P42574 2/20 0.40
SENP8 Q96LD8 2/20 0.40
SENP7 Q9BQF6 2/20 0.40
SENP6 Q9GZR1 2/20 0.40
TNKS O95271 1/20 0.40
MAPT P10636 1/20 0.40
THRB P10828 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7106470 0.84 PARP1 (0.65) LOXL2PARP1CDC25BKDM4EGAA
SCHEMBL6600286 0.79 LOXL2 (0.50) LOXL2PARP1CDC25BDAOAPAF1
SCHEMBL9541047 0.76 LOXL2 (0.57) LOXL2PARP1CDC25BKDM4EGAA
SCHEMBL31716561 0.76 LOXL2 (0.57) LOXL2PARP1CDC25BKDM4EGAA
SCHEMBL5214046 0.76 LOXL2 (0.57) LOXL2PARP1CDC25BKDM4EGAA
SCHEMBL31717057 0.76 LOXL2 (0.57) LOXL2PARP1CDC25BKDM4EGAA
SCHEMBL6046763 0.74 LOXL2 (0.68) LOXL2PARP1CDC25BKDM4EGAA
SCHEMBL6603861 0.73 LOXL2 (0.62) LOXL2PARP1CDC25BKDM4EGAA
SCHEMBL31717068 0.72 LOXL2 (0.53) LOXL2PARP1CDK4CCND1CDC25B
SCHEMBL5222703 0.72 CDC25B (0.58) LOXL2PARP1CDC25BKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1397350-A1 ISOQUINOLINONE DERIVATIVES AS PARP INHIBITORS Kudos Pharmaceuticals Limited (GB) 2004-03-17 EP disclosed
US-6664269-B2 Adminisetring isoquinolinone compounds for therapy of disease mediated by the enzyme poly(ADP- ribose)polymerase (\"PARP\") MAYBRIDGE PLC (GB) 2003-12-16 US disclosed
US-20030008896-A1 Isoquinolinone derivatives KUDOS PHARMACEUTICALS LIMITED (GB) 2003-01-09 US disclosed
WO-2002090334-A1 ISOQUINOLINONE DERIVATIVES AS PARP INHIBITORS KUDOS PHARMACEUTICALS LIMITED (GB) 2002-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030008896-A1 Isoquinolinone derivatives PARP1, PARP2, PARP3 LOXL2 3607/4885PARP1 1/4885CDK4 472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.